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Dr. Shaldon introduced the panel and then re- 
viewed the background to the launching of the in- 
terleukin-1 (IL-1) hypothesis in 1983. He stressed 
that in 1982 at the Tegernsee dialysis meeting of the 
German Clinical Society of Nephrology, Drs. 
Dinarello and Port had discussed mechanisms of 
fever in dialysis patients with contaminated dialy- 
sate. Subsequently, it was demonstrated that endo- 
toxin could pass the dialysis membrane, and that 
C5a could activate monocyte IL-1 production. Fol- 
lowing the cloning of IL-I in 1984 and tumor necro- 
sis factor (TNF) in 1985, it became obvious that 
both monokines were endogenous pyrogens and in- 
timately associated with the acute-phase response. 
Thus, the. scene was set to modify the name to the 
monokine hypothesis. 
Dr. Dinarello then reviewed the in vitro and ani- 
mal effects of recombinant IL-1B and TNF, and 
suggested that synergism between the two mono- 
kines was extremely important in achieving protein 
catabolism in rats as well as shock in rabbits. He 
then presented recent data using radioimmunoassay 
(RIA) methods for measuring these monokines in 
uremic plasma and confirmed the published bioas- 
say methods that there was a rise in both monokines 
during dialysis. 
Dr. Port reviewed his own work on attempting to 
demonstrate the induction of IL-1 from monocytes 
that were recovered from dialyzers after use. He 
suggested that even though the results were posi- 
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tive, the degree of activation was so small that it 
was dubious if they could be responsible for any of 
the clinical effects seen in long-term dialysis pa- 
tients. 
Dr. Kluger reviewed all the published work of 
Drs. Dinarello, Shaldon, Bingel, Koch, and Lonne- 
mann relevant to the IL- 1 hypothesis and concluded 
that although the hypothesis was ingenious, the 
data to date were not sufficiently convincing to sup- 
port the hypothesis. He started by quoting Thomas 
Huxley, “The great tragedies of science, the slaying 
of beautiful hypotheses by ugly facts,” and finished 
with another Huxley quote, “We are prone to see 
what lies behind their eyes rather than what appears 
before them.” 
In the lively discussion that followed, Dr. Shal- 
don quoted Popper on the unprovableness of any 
hypothesis and the need for modification in the light 
of new knowledge. He objected to Dr. Kruger’s 
mathematical analysis of qualitative bioassay data 
on IL-1 measurements and suggested that RIA 
methodology validated by bioassay would lead to 
more precise understanding of the problem. Dr. 
Dinarello agreed and pointed out that all the bioas- 
say data were measuring IL-6 as well as IL-1 and 
would need to be repeated. However, preliminary 
results suggested that TNF and IL-IB levels rose 
during dialysis when measured by RIA and were 
significantly higher than normal at their peak val- 
ues. He affirmed the need to modify the hypothesis 
and to call it the monokine hypothesis. However, 
both Dr. Shaldon and Dr. Dinarello were strongly of 
the opinion that the concept of dialysis activation of 
human blood monocytes by the membrane, C5a, 
dialysate endotoxin, and acetate was real and po- 
tentially detrimental for long-term dialysis patients. 
Drs. Port and Kruger remained unconvinced on the 
present evidence and reserved their judgment. 
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